Evolus Completes Key NUCEIVA Safety Study, Easing Risk for Aesthetic Toxin Investors
TipRanks (Thu, 14-May 12:32 PM ET)
Evolus Announces Commercial Launch of Estyme Injectable Hyaluronic Acid Gels in Europe
Business Wire (Mon, 11-May 8:30 AM ET)
Market Chameleon (Tue, 5-May 7:10 AM ET)
Business Wire (Mon, 4-May 4:05 PM ET)
Evolus to Report First Quarter Financial Results on May 4, 2026
Business Wire (Tue, 14-Apr 8:30 AM ET)
Telix Appoints David Gill as Non-Executive Director
Globe Newswire (Wed, 1-Apr 7:53 PM ET)
Evolus to Participate in the Needham 25th Annual Virtual Healthcare Conference
Business Wire (Tue, 31-Mar 8:00 AM ET)
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 20-Mar 4:05 PM ET)
Business Wire (Tue, 3-Mar 4:05 PM ET)
Evolus to Participate in The Leerink Partners Global Healthcare Conference
Business Wire (Wed, 25-Feb 8:00 AM ET)
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
Evolus trades on the NASDAQ stock market under the symbol EOLS.
As of May 18, 2026, EOLS stock price climbed to $6.60 with 182,136 million shares trading.
EOLS has a beta of -0.05, meaning it tends to be less sensitive to market movements. EOLS has a correlation of 0.00 to the broad based SPY ETF.
EOLS has a market cap of $434.64 million. This is considered a Small Cap stock.
Last quarter Evolus reported $73 million in Revenue and -$.16 earnings per share. This beat revenue expectation by $859,264 and missed earnings estimates by -$.02.
In the last 3 years, EOLS traded as high as $17.82 and as low as $3.86.
The top ETF exchange traded funds that EOLS belongs to (by Net Assets): VTI, IWM, VXF, IWO, SCHA.
EOLS has underperformed the market in the last year with a return of -34.0%, while SPY returned +26.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in EOLS shares. However, EOLS has outperformed the market in the last 3 month and 2 week periods, returning +53.5% and +23.8%, while SPY returned +8.3% and +2.2%, respectively. This indicates EOLS has been having a stronger performance recently.
EOLS support price is $6.25 and resistance is $6.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that EOLS shares will trade within this expected range on the day.
